INT94028

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1998
Last Reported 2010
Negated 3
Speculated 4
Reported most in Body
Documents 37
Total Number 41
Disease Relevance 22.41
Pain Relevance 5.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Twist1) nucleus (Twist1) DNA binding (Twist1)
transcription factor binding (Twist1)
Anatomy Link Frequency
neutrophils 2
Th1 cells 1
spinal cord 1
brain 1
trabecular bone 1
Twist1 (Mus musculus)
Pain Link Frequency Relevance Heat
cva 57 100.00 Very High Very High Very High
Hippocampus 17 99.24 Very High Very High Very High
sSRI 3 98.92 Very High Very High Very High
Inflammation 479 98.80 Very High Very High Very High
long-term potentiation 53 98.32 Very High Very High Very High
cerebral cortex 8 97.92 Very High Very High Very High
Pain 39 97.76 Very High Very High Very High
Spinal cord 9 97.64 Very High Very High Very High
cytokine 148 96.32 Very High Very High Very High
fluoxetine 6 94.68 High High
Disease Link Frequency Relevance Heat
Recurrence 61 100.00 Very High Very High Very High
Age-related Macular Degeneration 51 100.00 Very High Very High Very High
Paradoxical Embolism 11 100.00 Very High Very High Very High
Cancer 1417 99.98 Very High Very High Very High
Cognitive Disorder 94 99.80 Very High Very High Very High
Apoptosis 200 99.52 Very High Very High Very High
Small Cell Lung Carcinoma 14 99.32 Very High Very High Very High
Small Cell Lung Cancer 64 99.24 Very High Very High Very High
Non-small-cell Lung Cancer 57 99.20 Very High Very High Very High
INFLAMMATION 532 98.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rolipram is the prototypal PDE4 selective inhibitor, first described more than three decades ago [21], and it is generally admitted that at the dosage used in this study, rolipram has minimal inhibitory effect on other PDE families and does not interfere with unrelated signalling pathways [11].
Regulation (effect) of PDE
1) Confidence 0.44 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2563688 Disease Relevance 0.18 Pain Relevance 0.07
In addition, compliance is less of a problem using topical-PDT as the physician has total control over the treatment as opposed to topical treatments, eg, 5-FU, which should be used for a prolonged period (several weeks) and often lead to compliance problems.



Regulation (control) of PDT
2) Confidence 0.39 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503644 Disease Relevance 0.35 Pain Relevance 0.16
The Pa-PDT induced p-JNK caused down-regulation of the pro-apoptotic protein bcl-2 that facilitates the collapse of mitochondrial membrane and eventually initiates the intrinsic apoptotic pathway.
Regulation (regulation) of Pa-PDT associated with shock and apoptosis
3) Confidence 0.37 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2731730 Disease Relevance 0.67 Pain Relevance 0
The aim of the present study was to investigate the role of phosphodiesterase (PDE) enzyme inhibitors namely rolipram and theophylline in pain and inflammation in experimental animals.
Spec (investigate) Regulation (role) of PDE associated with pain and inflammation
4) Confidence 0.36 Published 2000 Journal Indian J. Exp. Biol. Section Abstract Doc Link 11233080 Disease Relevance 0.55 Pain Relevance 0.51
To confirm that the observed PDT effects are indeed due to the activation of the immune system we repeated the experiments with ?
Spec (observed) Regulation (effects) of PDT in immune system
5) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001867 Disease Relevance 0.96 Pain Relevance 0
The in vivo PDT-induced immune response led to an increased release of TNF?
Regulation (response) of PDT
6) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001867 Disease Relevance 0.99 Pain Relevance 0.05
Tumors escape PDT mediated immune surveillance by decreasing antigen expression
Regulation (escape) of PDT associated with cancer
7) Confidence 0.31 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001867 Disease Relevance 0.92 Pain Relevance 0
Because twist1 is expressed transiently upon activation of Th1 cells, we investigated whether signals from the TCR are involved in twist1 expression control.
Spec (whether) Regulation (control) of twist1 in Th1 cells
8) Confidence 0.27 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0 Pain Relevance 0
Targeting of twist1-expressing Th cells, by means of either addressing twist1 or a gene regulated by it, seems more promising, because it is more specific for repeatedly restimulated Th1 memory cells involved in chronic inflammation.
Regulation (regulated) of twist1 associated with inflammation
9) Confidence 0.27 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2525589 Disease Relevance 0.88 Pain Relevance 0.37
These data suggest deleterious effects for SSRIs, both on trabecular and cortical bone and a positive effect of PDE inhibitors on trabecular bone.
Regulation (effect) of PDE in trabecular bone associated with ssri
10) Confidence 0.25 Published 2007 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 17383703 Disease Relevance 0 Pain Relevance 0.58
We have developed FANA-modified antisenses oligonucleotides specifically targeting PDE isotypes 4B, 4D and 7A, as a potential new inhaled drug for the treatment of COPD.
Regulation (targeting) of PDE associated with pulmonary disease
11) Confidence 0.25 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.50 Pain Relevance 0.16
In the striatum and cerebral cortex the sGC activities and phosphorylation levels in vitro were significantly increased and were inhibited by PKA inhibitor. (3) The PDE activities showed no change in cerebellum and hippocampus, but in striatum and cerebral cortex PDE activities and phosphorylation levels in vitro were significantly increased and were inhibited by PKA inhibitor. (4) These changes described above were not observed in mice treated with naloxone 30 min prior to daily morphine injection.
Neg (no) Regulation (change) of PDE in hippocampus associated with narcan, hippocampus, cerebral cortex and morphine
12) Confidence 0.20 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.08 Pain Relevance 0.69
The PDT treated tumors showed the expected PDT response (more pronounced in the case of CT26.CL25), but since there were no effects on the size or growth rate of the contralateral untreated tumors in either case (Figure 4 F&G) mice could not be followed for long-term outcome.


Regulation (response) of PDT associated with cancer
13) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001867 Disease Relevance 1.08 Pain Relevance 0
Recently, a number of clinical trials have studied the potential effectiveness of the phosphodiesterase (PDE)-5 inhibitor sildenafil in the treatment of RE.
Regulation (effectiveness) of PDE
14) Confidence 0.16 Published 2004 Journal Drugs Section Abstract Doc Link 14723556 Disease Relevance 0.31 Pain Relevance 0.15
Interestingly, we observed that the dose required to achieve significant inhibition of the three PDE targets at the mRNA level (0.2 mg/kg/day) was the same as the dose required to block the recruitment of neutrophils, KC and pro-MMP-9.
Regulation (targets) of PDE in neutrophils
15) Confidence 0.11 Published 2009 Journal Respir Res Section Body Doc Link PMC2696437 Disease Relevance 0.30 Pain Relevance 0.12
For PDT a relapse rate of 17% after 64 months was reported (Leman et al 2002) suggesting a comparable long-term efficacy of PDT and other established treatment options.
Regulation (efficacy) of PDT associated with recurrence
16) Confidence 0.08 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621408 Disease Relevance 0.54 Pain Relevance 0.32
PDT controls consisted of photosensitizer and light treatment as described above but in the absence of ETXp administration.


Regulation (controls) of PDT
17) Confidence 0.07 Published 2009 Journal J Neurooncol Section Body Doc Link PMC2773371 Disease Relevance 0.58 Pain Relevance 0
Because IVB monotherapy reduces exudative changes, IVB might have a role in combination therapy with PDT.[18] In AMD, increased expression of VEGF has been reported in the CNV of eyes after PDT.[21] This elevated expression of VEGF following PDT might potentially increase the risk of CNV recurrences.[21] Similarly, the addition of IVB to PDT for PCV might counteract the up-regulation of VEGF following PDT and might prevent the recurrence of polyps.
Regulation (regulation) of PDT in eyes associated with polyps, age-related macular degeneration and recurrence
18) Confidence 0.07 Published 2010 Journal Indian Journal of Ophthalmology Section Body Doc Link PMC2907029 Disease Relevance 1.15 Pain Relevance 0
In the striatum and cerebral cortex the sGC activities and phosphorylation levels in vitro were significantly increased and were inhibited by PKA inhibitor. (3) The PDE activities showed no change in cerebellum and hippocampus, but in striatum and cerebral cortex PDE activities and phosphorylation levels in vitro were significantly increased and were inhibited by PKA inhibitor. (4) These changes described above were not observed in mice treated with naloxone 30 min prior to daily morphine injection.
Neg (no) Regulation (change) of PDE in cerebellum associated with narcan, hippocampus, cerebral cortex and morphine
19) Confidence 0.07 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016853 Disease Relevance 0.08 Pain Relevance 0.69
In spite of this, ALA methyl ester has been shown to be effective for PDT of nodular basal cell carcinoma59,132,133 where ALA PDT has historically produced poor results.134,135 However, it should be pointed out that these clinical studies used curettage/debulking to remove the stratum corneum and some of the carcinoma before treatment, and also routinely used a 1–2 treatment cycles that each involved two treatments a week apart.
Regulation (effective) of PDT in basal cell associated with carcinoma
20) Confidence 0.05 Published 2007 Journal Perspectives in Medicinal Chemistry Section Body Doc Link PMC2754918 Disease Relevance 0.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox